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Abstract 
Relapsed/refractory multiple myeloma (rrMM) remains a difficult condition to treat, despite the 
availability of new drugs. In this review, we searched for evidence to guide physician in the choice 
of salvage therapy in certain subgroups of patients. We tried to provide evidence-based information 
and to suggest possible approaches based on data on prior therapies, prior remission duration, 
toxicity of prior treatments, patient’s comorbidities and disease characteristics at relapse. 
Unfortunately, little evidence is available, there are no large and/or randomized trials nor direct 
comparisons of drugs or combinations for rrMM patients to draw any definite conclusion. Almost 
all the studies presented here suggest that depth of response is a key factor also for patients with 
rrMM. Which one between combinations and sequential therapies is the best approach remains 
controversial. Several studies favor the former approach in early relapse, since it leads to a higher 
complete response rate, regardless of prior therapies. However, in both strategies, achieving 
maximal response should always remain a main goal. Consolidation/maintenance therapy is 
beneficial both in combination or sequential therapies also in rrMM. Second generation new-drugs, 
such as pomalidomide, carfilzomib, bendamustine and histone-deacetylase inhibitors, will probably 
expand the rescue possibilities also in this setting. 
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Introduction 
Novel agents, namely the immunomodulatory drugs Thalidomide and Lenalidomide, and the 
proteasome inhibitor Bortezomib, were tested in different clinical trials and led to good results in 
patients with multiple myeloma (MM). In particular, benefits with novel agents were also seen in 
relapsed/refractory multiple myeloma (rrMM) 1 . 
Besides the approved regimens, new combinations containing novel drugs with/without 
conventional chemotherapies and/or steroids have been studied for the treatment of rrMM. To date, 
no comparative studies are available to help physicians choose the best treatment for rrMM patients. 
Treatment choice for rrMM is based on prior therapy, remission duration and toxicity of treatment, 
patient’s comorbidities and disease characteristics at relapse. Direct evidence and more precise 
guidelines are needed.  
This review reports on the latest data and evidence about treatment of rrMM.  
 
Is quality of response a critical end-point? 
In newly diagnosed multiple myeloma (MM) patients, a complete response (CR) is a surrogate 
marker of  long-term outcome. After the introduction of novel drugs, CR has become a more 
achievable aim, also for rrMM patients. However, the role of CR in these patients needs to be 
validated. Table 1 summarizes the studies addressing this issue. A retrospective study investigated 
the relationship between response rate and outcome in more than 300 patients with rrMM treated 
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with thalidomide  dexamethasone. In this study, the achievement of CR and very good partial 
response (VGPR) was associated with a significantly longer progression-free survival (PFS) and 
overall survival (OS) compared with partial response (PR) and stable disease (SD) 2 . In another 
retrospective analysis on rrMM patients treated with the combination of Doxil, Vincristine, low-
dose dexamethasone and Thalidomide (DVd-T) found that patients achieving CR/VGPR had a 
significantly better PFS and OS compared with those achieving PR/SD 3 . 
In the randomized phase III APEX trial, a post-hoc analysis including patients treated with 
bortezomib as single agent showed a relation between CR and both better treatment free interval 
(TFI) and better time to alternative therapy (TTAT), although time-to-progression (TTP) and OS 
were similar 4 . These results were consistent with those reported in a retrospective analysis on 70 
patients treated with bortezomib  dexamethasone 5 . Patients obtaining CR/VGPR had a 
considerably better TTP, TTAT, TFI compared with those achieving PR. In another study, the 
combination of bortezomib with doxorubicin and dexamethasone led to a significant higher event-
free survival (EFS) in patients obtaining CR/VGPR if compared with PR 6 . In a recent 
observational study, 769 patients were treated with bortezomib-based therapy. After at least 4 
courses of therapy, CR rate was 12% and near CR (nCR) 16% 7 . These patients had a significantly 
improved survival compared with those who did not achieved CR and nCR. Another trial assessed 
the role of the 4-drug combination Thalidomide-Doxil-Dexamethasone-Bortezomib (ThaDD-V) 8 . 
Patients who achieved CR had a significantly longer PFS compared with those achieving a lower 
response. In this study, patients attaining a stringent CR (sCR) had a better outcome than those 
achieving CR only. This demonstrates the importance of a deeper response also in rrMM. 
A post-hoc analysis pooled data from two trials comparing patients treated with lenalidomide and 
high-dose dexamethasone[9]. In this analysis, patients achieving CR/VGPR had a significantly 
better TTP and OS compared with those achieving PR. This benefit was independent of when 
CR/VGPR was achieved and it was confirmed by a landmark analysis at 12-months. However, the 
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two groups of patients were not well balanced. Patients who achieved CR/VGPR had a shorter 
disease history and received less prior treatments, particularly with thalidomide. No adjustment for 
these important factors was made in this study, and this is a major limitation.  
These studies suggest that rrMM patients who achieve deeper response have a better outcome, at 
least in terms of PFS. These data should be considered with caution, since they derive from 
retrospective studies. Well-designed prospective studies are warranted to establish the relationship 
between response and outcome in rrMM. 
 
Choosing treatment for patients with suboptimal response to induction regimen 
Overall response rate (ORR/ at least PR) after first-line therapy with novel agents accounts for 57-
100% 10-12 . MM patients considered “truly” refractory to induction therapy,i.e. those who fail to 
reach at least PR after three cycles of induction with novel agent-containing therapy, as defined in  
recent guidelines provided by an international panel of experts 13 ,  may need salvage treatment 
In the non-transplant setting, the role of therapy aiming to improve depth of response should be 
investigated. No benefit with this approach was seen in elderly patients failing to reach at least PR, 
since these patients may have difficulties in prolonging treatment. Better quality of response was 
associated with improved long-term outcomes with VMP treatment, regardless of whether best 
response, in particular CR, was achieved early or late (even after 24 weeks of treatment). This was 
particularly evident in older patients and in those with high serum 2-microglobulin levels or higher 
tumor burden (ISS stage II or III) 14 . Prolonging lenalidomide-based treatment was linked to an 
improvement in quality of response 15 . These data suggest that initial treatment should be 
continued beyond first response, if tolerated, in order to achieve higher quality response. Ongoing 
or future prospective trials addressing this issue will validate this approach. This should be always 
considered an individualized approach and should be based on patient’s characteristics such as age, 
performance status, presence of comorbidities, type of previous therapy, quality of response 
achieved, tolerance to therapy, side-effects of drugs. Some important aspects should be considered, 
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such as risk of disease, possible worsening of quality of life due to prolonged treatment, poor 
outcome after relapse/refractory to novel agents, and drug resistance at relapse. These factors may 
reduce the spectrum of new therapeutic options that can be used. However, stabilization of a 
symptom-free condition despite evidence of persistent disease should remain a major goal in unfit 
elderly patients, while, in the other patients, treatment should aim at achievement of the best 
possible response. 
In the transplant setting, not achieving at least PR after induction therapy with old agents did not 
affect PFS or OS, and a response was achieved after transplantation 16,17 . However, different 
outcomes were reported according to the depth of response achieved. Conversely, a recent 
retrospective analysis of 286 patients showed that failure to respond to immunomodulatory-based 
(IMiD, thalidomide or lenalidomide) induction treatment leads to significantly shorter post-
transplant PFS and OS 18 . This study also suggested that the mechanisms underlying resistance to 
IMiD therapies are similar to those with high-dose melphalan. This observation raises the question 
of whether patients not responding to induction regimens including novel agents should be 
immediately treated with alternative therapies before transplant. 
So far, induction therapy has aimed to achieve the deepest and fastest response before 
transplantation. No data are currently available on possible consolidation after induction and before 
transplantation for patients achieving “suboptimal” response to induction. New studies are ongoing 
to further improve the results obtained after induction treatments, by reducing doses (thus 
increasing tolerability), adding a fourth drug to the regimen used, or combining the two most potent 
agents (bortezomib and lenalidomide) 19-21 . Besides risk-adapted therapies, in the near future, 
response-adapted strategies may have a fundamental role to choose treatment and to further 
improve outcome. 
 
How many drugs in rrMM? 
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Three- and 4-drug combinations improve CR rate and outcome of newly diagnosed MM 22 .  Is it 
the same also for rrMM? 
The CR rate with approved single- or 2-agent therapies for rrMM such as bortezomib 23  
lenalidomide 24 , bortezomib-doxil 25  and lenalidomide-dexamethasone 26,27  ranges from 2 to 
15%, TTP from 5 to 11 months. Many 3- or 4-drug combinations have been recently studied in 
phase I-II studies in patients with rrMM. CR rates and PFS of the main regimens used in rrMM are 
reported in the Fig. 1. Data show that a more intense approach leads to higher CR rate and 
subsequently to better outcome. Three- or 4-drug combinations containing thalidomide, bortezomib, 
dexamethasone and anthracyclines showed the best results in rrMM, CR rates approximately 
doubled and PFS improved if compared with single- or 2-agent regimens. Toxicity is not always 
strictly associated with the number of drugs used. As showed in Table 2, the incidence of 
neutropenia, infections and DVT with regimens including 3 or 4 drugs were comparable with those 
reported with 2-drug combinations. However, thrombocytopenia and neuropathy are more common 
when 3- or 4-drug combinations including bortezomib are used. In order to improve outcome by 
reducing toxicity, some studies demonstrated that reducing bortezomib schedule from twice- to 
once-weekly administration significantly decreases bortezomib-induced peripheral neuropathy 28-
30 . These more complex regimens are beneficial also in rrMM, provided that patients have not 
particular contraindications, such as neuropathy, and if they are able to tolerate potential toxicities 
associated with such combinations, for instance thrombocytopenia and neuropathy. Replacing 
thalidomide with lenalidomide and reducing bortezomib dose-intensity may improve outcome and 
decrease non-hematological toxicity. 
 
How long should rrMM therapy last? 
In newly diagnosed MM, prolonged or continuous therapy (i.e. consolidation-maintenance) is 
associated with higher quality of response and translates into better outcome 28,31-35 . Treatment 
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duration is a burning question also in rrMM. Whether  induction therapy should be limited to 6-9 
courses and repeated if necessary, or if it should be prolonged or continued until progression 
remains an open issue.  
Limited therapy with 3- or 4-drug combinations (i.e. lenalidomide-adriamicyn-dexamethasone 
[RAD] or bortezomib-melphalan-prednisone-thalidomide [VMPT]) 36,37  do not improve the 
results obtained with 2-drug regimens such as lenalidomide-dexamethasone (LD) 38  or 
bortezomib-dexamethasone (VD) 39  whereas consolidation plus maintenance (i.e. bortezomib-
adriamicyn-dexamethasone [PAD] followed by thalidomide-dexamethasone consolidation (TD) and 
thalidomide maintenance, or thalidomide-dexamethasone-doxil-bortezomib [ThaDD-V] followed 
by VD/TD consolidation and thalidomide maintenance) 8,40  after induction with regimens 
containing bortezomib triples CR rate and improves PFS.  
Four-drug combinations such as dexamethasone-bortezomib-doxorubicin-lenalidomide (DVd-
R) 41  or lenalidomide-melphalan-prednisone-thalidomide (RMPT) 42  followed by maintenance 
with lenalidomide do not seem to improve outcome compared with continuous LD. 
Some studies investigated re-treatment with bortezomib after an adequate rest period. Patients 
enrolled in VISTA trial, who relapsed after VMP and were re-treated with bortezomib, had a CR 
rate similar to patients treated with lenalidomide- or thalidomide-based salvage therapy 30 . 
Ongoing prospective study (RETREIVE study) demonstrated that re-treatment with bortezomib is 
feasible and safe but the benefits of this strategy needs to be confirmed 43 . 
A recent sub-analysis pooled MM-09 and MM010 studies[9]. Patients achieving PR after induction 
with LD had 50% probability of obtaining CR/VGPR with further treatment and this response 
upgrade translated into a better outcome. However, in this study, 60% of patients tolerated and 
continued therapy after induction, and only 30% remained in the landmark analysis at 12 months. 
Long-term treatment with LD is feasible and well-tolerated although severe hematologic toxicity, 
infections and thrombosis are a considerable drawback. Further investigation will define clinical 
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and biological characteristics of patients who are more likely to benefit from long-term therapy. To 
date, no specific study has assessed which is the patient population that benefits more from this 
approach. In particular, the role of prolonged treatment remains controversial in elderly patients for 
whom long-term therapy may be detrimental. Therefore, a close evaluation of the risk/benefit ratio 
is warranted.  
 
What is the impact of prior therapy?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Most young and elderly patients with newly diagnosed MM are currently treated with combinations 
containing at least one new drug. Identifying the best approach at relapse is difficult, especially 
considering that all patients have already been exposed to thalidomide, lenalidomide and 
bortezomib. Moreover, few data about the impact of prior therapies on quality of response and 
outcome in patients with rrMM are available. Before the introduction of novel agents, duration of 
response progressively shortened with subsequent regimens 44 . Similarly, patients who relapsed or 
became refractory to novel agents show a poor outcome in terms of both PFS and OS 45 .  
As shown in Fig. 2, in two studies, the number of previous therapy did not significantly impact on 
response rate in relapsed/refractory MM patients receiving either bortezomib 23  or lenalidomide 
monotherapy 24 . Patients included in these two studies were not matched for number of prior 
therapies (2 or fewer prior treatment regimens versus 3 or more in patients treated with 
lenalidomide; one  prior line of therapy versus more than one in those receiving bortezomib). In 
patients heavily pre-treated, bortezomib led to a response rate similar to patients who received 
lenalidomide alone (at least PR 34% vs 26%). Considering the toxicities associated with 
lenalidomide/bortezomib and the possible presence of comorbidities, these agents could be used 
alone in elderly or frail heavily pretreated rrMM patients for whom preserving quality of life is 
essential. 
A subset analysis of MM-009/MM-010 trials assessing LD, reported a higher ORR rate (67% vs 
57%) and significantly longer PFS (14 months vs 9.5 months; p=0.047) and OS (median not 
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reached vs 30.8 months; p=0.028) in patients receiving only one prior therapy 46 . These results are 
consistent with those obtained in a retrospective analysis on patients receiving LD where a higher 
number of prior regimens was associated with lower ORR 47 . However, this trend was not 
confirmed in studies including patients treated with 3- or 4-drug combinations. ORR obtained in 
patients receiving bortezomib-lenalidomide-dexamethasone (VRD) 48  and PAD 6  was not 
affected by the number of prior therapies. Of note, responses with PAD as second-line treatment (at 
least PR=80%; CR=13.5%) were similar to PAD as fourth-line treatment (at least PR=64%; 
CR=12%), and no significant difference in term of 1-yr EFS was detected between patients 
receiving PAD as second-line or beyond 6 . On the contrary, VMPT regimen is more effective at 
early-stage disease, leading to a CR rate of 36% compared with 0% in patients heavily pretreated. 
This also translated into a significantly higher PFS (1-yr 100% vs 27%; p=0.009) 37 . Similar 
results were obtained with ThaDD-V combination 8 . No definite data are available to explain how 
prior therapies may impact on outcome of the 3- and 4-drug combinations described above. 
However, in patients who received one prior therapy, VMPT and ThaDD-V induce CR rates similar 
to those obtained in newly diagnosed MM. Conversely, CR rate after PAD regimen is unexpectedly 
low in these patients, and is comparable to results obtained with lenalidomide plus dexamethasone 
(Fig. 2). It is not clear if such results depend on the different study population, the limited number 
of patients enrolled, or any other reason. Of note, these more intense approaches are associated with 
grade 3-4 neutropenia, infection and peripheral neuropathy, hence they may be more suitable for 
younger patients or compliant patients at early relapse phase. 
As for the type of previous therapies, mainly data on thalidomide and its impact on salvage therapy 
are available. Thalidomide was introduced before bortezomib and lenalidomide, and it has in fact 
been used more extensively. Data about previous therapy with thalidomide, summarized in Fig. 3 
and Fig. 4, are quite conflictng  Patients receiving bortezomib alone 49  showed worse response 
and outcome if they had received prior thalidomide; on the contrary, no differences in terms of 
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ORR and TTP were found in patients previously treated or not with thalidomide and receiving 
bortezomib plus pegylated liposomal doxorubicin 50 . Pooled data from MM-009/MM-010 trials 
showed that ORR and TTP were significantly lower in patients with prior thalidomide exposure, 
suggesting the possibility of a cross-resistance between thalidomide and lenalidomide. However, in 
this study, patients previously treated with thalidomide had a significant higher number of prior 
lines of therapy and a longer time from diagnosis 51 . These results are partly in contrast with those 
from a French retrospective analysis on patients treated with LD[47]. In this study, response rate 
and PFS were not affected by prior thalidomide, although progression on thalidomide negatively 
affected both PFS and OS. This may suggest the negative impact of thalidomide maintenance 
therapy[47,52]. Nevertheless, a recent retrospective study, including a wide cohort of heavily 
pretreated patients, demonstrated that lenalidomide is effective in patients both thalidomide-
resistant or sensitive to a previous thalidomide-therapy. 53  Although only retrospective analyses 
are currently available, prior thalidomide seems to not affect salvage therapy with lenalidomide.  
More complex regimens, such as the combinations bortezomib-dexamethasone-cyclophosphamide 
(BCD) 54 , bortezomib-thalidomide-dexamethasone (VTD) 55 , bortezomib-lenalidomide-
dexamethasone (VRD) 48  showed a significant higher efficacy in patients who did not receive 
prior treatment with thalidomide or who are not resistant to it (Fig 4).  
The impact of previous therapy with bortezomib is controversial. As reported in Fig. 5, two 
studies[26,47] with LD showed conflicting results: in one study previous bortezomib did not affect 
ORR, while in the other one ORR, PFS and OS were significantly better in patients who had not 
been previously treated with bortezomib. However, the two patient populations did not match for 
median number of previous regimens (2 vs 4, respectively). In the MM-016 study, multivariate 
analysis in patients treated with LD showed that prior bortezomib is an adverse risk factor affecting 
PFS and OS 56 . In contrast with VRD regimen 48 , ORR of patients who received PAD regimen 
was not affected by prior bortezomib exposure, showing the efficacy of bortezomib in consecutive 
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lines of therapies 6 . This was also confirmed in another study using ThaDD-V combination 8 .  
The recent update analysis of the VISTA trial shows that bortezomib administered as first-line 
treatment does not negatively affect response to lenalidomide-, thalidomide- or bortezomib-based 
regimens at relapse 30 . Data on the impact of previous bortezomib on subsequent salvage therapies 
are limited and conflicting, and they mainly derive from retrospective studies including small 
number of patients. Therefore, no definitive conclusion can be drawn 6,8,48 . 
With regard to salvage treatment following LD, bortezomib-based regimens[57] in heavily 
pretreated patients led to at least PR rate 43% and prolonged. Another study on patients previously 
treated with lenalidomide, bortezomib in combination with lenalidomide and dexamethasone 
showed encouraging results (at least PR = 57%; CR = 15%) 58 . Lenalidomide, cyclophosphamide 
and prednisone (REP) may be another alternative option in this setting. In one trial, REP induced a 
response rate of 50% (CR = 14.3%) in patients refractory to LD 59 .  On the contrary, thalidomide-
based therapies do not exert a substantial activity in patients who received prior treatment with 
lenalidomide, although only results from very small study are available 60 .  
A prior stem cell transplantation does not seem affect response and outcome in patients receiving 
new-drug combinations 48,49,61 . In patients who relapsed after single or tandem autologous stem 
cell transplantation (ASCT), a recent Italian study reported a significant higher response rate in 
patients receiving ASCT as second-line compared with those treated with thalidomide/bortezomib 
based-regimens (85% vs 49%; p=0.0004). However, no differences in terms of PFS or OS were 
detected between two groups of patients 62 .   
 
What is the impact of cytogenetics in rrMM? 
The prognostic value of chromosomal abnormalities such as del(13), t(4;14) or del(17p) has not 
been well defined in rrMM patients treated with new drugs since no prospective, randomized  trials 
have been performed yet. In most retrospective analyses of phase II/III studies including patients 
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receiving single-agent or new drug combinations, del(13) by FISH was not associated with a 
significant lower ORR and a shorter TTP/PFS 47,56,6365 . Jagannath and colleagues evaluated the 
impact of del(13) identified by either FISH or methaphase cytogenetics on response and outcome in 
patients receiving bortezomib in SUMMIT and APEX trials. This study  found no adverse 
prognostic impact of del(13) also by conventional cytogenetics, but the number of patients included 
was considerably small 64 . However, in a Korean study assessing a four-drug combination 
(bortezomib, cyclophosphamide, thalidomide, dexamethasone) reported a PFS significantly shorter 
in patients with del(13) by FISH compared with those with normal karyotypes 66  (Fig. 6 and Fig. 
7). In a small Canadian study 65 , bortezomib seems to be effective in patients with t(4;14) 
abnormality, while results from studies using LD combination are conflicting 47,56 . Neither 
bortezomib- or lenalidomide-based combination proved to overcome poor prognosis associated with 
17p deletion 36,56,65 . However, no definitive conclusion can be drawn from these small 
retrospective trials. Moreover, other prognostic factors could be somewhat more relevant than 
cytogenetics in advanced disease.  
 
An overview of  new drugs of second generation 
Recent early phase I and II
 
clinical trials
 
using new proteasome inhibitors, third-generation IMiDs 
and
 
alkylating agents have produced encouraging results in terms of both efficacy and toxicity. 
Novel proteasome inhibitors, such as carfilzomib (CFZ; PR-171) 67   salinosporamide (NPI-
0052) 68   and CEP18770 69 , will soon become part of clinical therapy. Preliminary clinical
 
data 
on CFZ have been reported, while less information
 
is available on NPI-0052 or CEP18770. CFZ is a 
new proteasome inhibitor that binds its target selectively and irreversibly 67,70 . Preclinical studies 
showed that CFZ was more potent in its ability to induce caspase-8 and caspase-9 than BTZ and 
could overcome bortezomib-resistance in cell lines and primary plasma cell models 67 . After 
phase I studies targeting B-cell-derived malignancies 71,72 , several phase I/II studies investigated 
 14 
the role of CFZ in patients with rrMM. In PX-171-003 study, 266 patients received  CFZ 20 mg/m
2
 
on days 1, 2, 8, 9, 15, 16 of a 28-day cycle and, after first cycle, CFZ dose was escalated to 27 
mg/m
2
. Patients had received a median of 5 prior lines of therapy (range 1-20)  including 
bortezomib (99.6%), thalidomide (74%), lenalidomide (94%) and stem cell transplantation (65%). 
Sixty-five percent of patients were refractory to bortezomib. At least PR was reported in 24% of 
patients, with a median duration of response of 7.4 months. Main grade 3-4 side effects were 
thrombocytopenia (22%), anemia (20%) and pneumonia (8%) whereas severe peripheral 
neuropathy was documented in less than 1% of patients 73 .  A recent safety analysis evaluating 
pooled data from more than 600 patients enrolled in 4 trials confirmed that CFZ rarely induced  
grade 3 peripheral neuropathy 74  and, due to excellent tolerability it can be administered for 
prolonged periods 75 . Recent studies have reported encouraging preliminary safety and efficacy 
results with CFZ in patients with renal impairment (RI) 76,77   and with cytogenetic abnormalities 
78 . A phase Ib dose-escalation study, evaluated CFZ in association with lenalidomide and low-
dose of dexamethasone (CRd) in 40 heavily pre-treated rrMM patients. ORR for the 29 evaluable 
patients was 59% and median duration of response (DOR) has not been reached (median follow-up 
5.2 months). No dose-limiting toxicities (DLTs) or deaths attributed to therapy have been observed. 
The most common ≥ grade 3 adverse events were hematological (thrombocytopenia [n=6], anemia 
[n=4], and neutropenia [n=6]), and all were reversible. No treatment-related neuropathy, or 
thrombotic events ≥ grade 3 were observed 79 . Based on these data, a Phase III international trial 
of CRd vs lenalidomide plus low-dose dexamethasone (Rd) in relapsed MM was started in 2010. 
Pomalidomide (POM, CC4047) is another IMiD recently introduced 80,81 . In vitro studies showed 
that POM is more potent than the other IMiDs 82-84 . In a phase I study, POM was given at 4 dose 
levels (2, 3, 4, 5 mg) on days 1–21 of 28-day cycle, and 32 patients were included. Median number 
of prior regimens was 7 (range 2–18). MTD has not yet been reached. Eight of 21 (38%) patients 
treated with POM alone achieved a response (1 CR, 2 PR, 5 MR); mean TTP was 8.3 weeks (range 
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2–36). In 5 of 13 patients (38%), responses improved after dexamethasone was added (2 PR, 2 MR, 
1 SD). Neutropenia and thrombocytopenia were the most common grade 3/4 toxicities, with no 
dose-dependent increase 85 . In the first phase II trial,
 
60 patients with rrMM received POM 2 mg 
daily orally, on days 1 through 28 of a 28-day cycle and dexamethasone
 
40 mg daily on days
 
1, 8, 
15, 22 of each cycle. Thirty-eight patients achieved objective responses (63%) including
 
5% of CR 
and 28% of VGPR. Response rates achieved in lenalidomide- (40%) 86,87 , thalidomide- (37%) 
and bortezomib-refractory patients (60%) 86  were also promising, and so was long-term response 
found in an extended follow-up of phase I study 88 . 
The alkylating agent bendamustine is structurally similar
 
to both alkylating agents and purine 
analogs, and is not cross-resistant
 
with alkylating agents and other drugs in vitro 89 . Bendamustine 
showed strong activity in
 
MM patients, also in untreated patients 90,91 . Recently, a phase I study 
investigated the role of bendamustine in combination with lenalidomide and dexamethasone in 
patients with rrMM[92]. Seven out 9 valuable patients (67%) achieved a  response, including 1 
VGPR and 5 PRs. The MTD of bendamustine and lenalidomide has not been identified at this point. 
Grade 3/4 adverse events included neutropenia (2 patients), thrombocytopenia (1), anemia (1), 
hyperglycemia (1), and prolonged QT interval (1). 
Several other agents targeting novel molecular mechanisms are in late-stage clinical
 
testing (Table 
3). Unfortunately, to date none of these trials has yet reported
 
significant single-agent activity, since 
some of these agents may result in a more cytostatic than
 
cytotoxic effect. Some of these 
compounds
 
have also been used in combination with bortezomib or lenalidomide in phase
 
Ib/II 
trials; however, it is difficult to identify the benefit of these agents
 
when they are used in 
combination with active agents 93 . Numerous other investigational agents are being considered for
 
early-phase clinical testing. Therapeutic options for MM will continue to increase, and this will 
substantially improve outcomes. 
Expert opinion 
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To date, there is no strong evidence to guide physicians in the treatment choice for rrMM, and 
mainly post-hoc analyses are available. Randomized studies are awaited in this context.  
First-line therapy choice plays an important role. All compliant patients should receive combination 
therapy followed by intensification and maintenance with the aim to obtain maximal tumor burden 
reduction. Valid options are currently available. 
The studies described in this review suggest that depth of response is a key factor also in rrMM 
patients. Indeed, patients attaining a deeper response, in particular CR, have a prolonged PFS.  
In patients with suboptimal response to induction, type of therapy represents another crucial point. 
The data presented here also suggest that in the non-transplant setting, therapy should be prolonged, 
if tolerated, beyond first response, with the aim of achieving deeper response. However, caution is 
necessary, and patients’ characteristics, such as age, performance status, comorbidities, type of 
previous therapy, response and tolerance to previous treatments should be taken into account. In 
younger patients, data are controversial, and the role of prolonged treatment in patients failing to 
achieve the deepest and fastest response before transplantation remains an open issue. Before the 
introduction of novel drugs, young patients with suboptimal response to induction benefited most 
from early transplantation. However, in the era of new drugs, new data have questioned whether 
transplantation should be preformed early or if second-line treatment should be preferred to 
improve response before high-dose therapy.  
Data reported in published studies showed that more intense treatment regimens including 3 of 4 
drugs proved to be beneficial in rrMM. Of course, the toxicity profile of these regimens should be 
carefully considered. To decrease toxicity and eventually treatment discontinuation, replacing 
thalidomide by lenalidomide, and reducing bortezomib schedule from twice- to once-weekly 
administration seem to be effective actions. 
As for the type of previous treatment, in patients who received prior treatment with thalidomide, 
bortezomib alone, as well as BCD, VTD, and VRD, led to negative results, while conflicting results 
were reported with LD. One study also suggested cross-resistance between thalidomide and 
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lenalidomide. Prior treatment with bortezomib appeared to negatively impact on outcome in 
patients receiving VRD, while it did not affect patients treated with PAD combination. Similarly to 
prior treatment with thalidomide, results with LD are conflicting in patients previously treated with 
bortezomib. Prior treatment with lenalidomide positively impacted on patients treated with VRD, 
but no substantial advantage was seen in patients who received thalidomide-based regimens. 
However, in our opinion, young and compliant patients in first or, at most, second relapse, who 
have not received multi-drug combination therapies, or who have shown an optimal outcome with 
them, should receive a combination therapy containing bortezomib, one IMiD, dexamethasone, and 
possibly one chemotherapeutic agent. This approach aims to obtain a CR, as well as long-term 
remission duration. On the contrary, younger patient non-compliant with or having a suboptimal 
outcome after multi-drug combination therapies, elderly patients, and those in third or subsequent 
relapse, should receive sequential therapy based on the type, side effects and effectiveness of prior 
therapies. Patient comorbidities, aggressiveness of disease and patients’ preference should be 
considered as well, since there is no evidence to support a specific treatment choice in certain 
subgroups. The achievement of maximal response should always remain a main goal. Thalidomide 
with or without steroids may be more suitable in advanced stage of disease. If side effects and 
complications occur, palliative and supportive therapies to maintain quality of life are a reasonable 
option.  
Consolidation and/or maintenance therapy seems to be of benefit both in combination or sequential 
therapies also in rrMM. Caution is necessary when using long-term thalidomide since a prolonged 
exposure to thalidomide may cause peripheral neuropathy, thus limiting the choice of subsequent 
therapies. On the contrary, lenalidomide seems to be the best candidate for long-term treatment 
given its safety profile and effectiveness.  
To date, there is not sufficient evidence to base therapy choice for rrMM on cytogenetics.  
Second generation new-drugs, such as pomalidomide, carfilzomib, bendamustine and histone-
deacetylase inhibitors, showed promising preliminary results. They will probably enter the clinical 
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practice soon, thus expanding the treatment spectrum of multi-drug combinations, and eventually 
increasing the rescue possibility.  
Ongoing and future studies will increase the treatment options available to rrMM patients and 
improve outcome 
 
.   
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